Amyloid-β protein impairs Ca2+ release and contractility in skeletal muscle

Neurobiology of Aging

Volumn 31, Issue 12, 2010, Pages 2080-2090

  Shtifman, Alexander ^a   Ward, Christopher W ^b   Laver, Derek R ^c   Bannister, Mark L ^d   Lopez, Jose R ^e,f   Kitazawa, Masashi ^g   LaFerla, Frank M ^g   Ikemoto, Noriaki ^d   Querfurth, Henry W ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloid; APP; Excitation contraction coupling; Inclusion body myositis; Ryanodine receptors

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CALCIUM ION; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CALCIUM TRANSPORT; CHANNEL GATING; CONTROLLED STUDY; IN VITRO STUDY; LIPID BILAYER; MOUSE; MUSCLE CONTRACTILITY; MUSCLE FATIGUE; MUSCLE FORCE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; SKELETAL MUSCLE; TRANSGENIC MOUSE;

AMYLOID BETA-PEPTIDES; ANIMALS; CALCIUM; CALCIUM SIGNALING; CATIONS, DIVALENT; MICE; MICE, TRANSGENIC; MUSCLE CONTRACTION; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; PEPTIDE FRAGMENTS; RABBITS;

EID: 78650171972     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.11.003     Document Type: Article

References (49)

1. Allen D.G., Kabbara A.A., Westerblad H. Muscle fatigue: the role of intracellular calcium stores. Can. J. Appl. Physiol. 2002, 27:83-96.
2. Allen D.G., Lamb G.D., Westerblad H. Impaired calcium release during fatigue. J. Appl. Physiol. 2008, 104:296-305.
3. Ambroggio E.E., Kim D.H., Separovic F., Barrow C.J., Barnham K.J., Bagatolli L.A., Fidelio G.D. Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1-42: a membrane-disrupting peptide. Biophys. J. 2005, 88:2706-2713.
4. Arispe N. Architecture of the Alzheimer's A beta P ion channel pore. J. Membr. Biol. 2004, 197:33-48.
5. Arispe N., Pollard H.B., Rojas E. Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:10573-10577.
6. Arispe N., Rojas E., Pollard H.B. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:567-571.
7. Askanas V., Engel W.K. New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies. Curr. Opin. Rheumatol. 1995, 7:486-496.
8. Askanas V., Engel W.K. Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion body myositis, cultured human muscle, and transgenic mice. Am. J. Pathol. 1998, 153:1673-1677.
9. Askanas V., Engel W.K. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Curr. Opin. Rheumatol. 1998, 10:530-542.
10. Askanas V., Engel W.K. Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging. Scand. J. Rheumatol. 1998, 27:389-405.
11. Askanas V., Engel W.K. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006, 66:S39-S48.
12. Askanas V., McFerrin J., Baque S., Alvarez R.B., Sarkozi E., Engel W.K. Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:1314-1319.
13. Askanas V., Serratrice G., Engel W.K. Inclusion-Body Myositis and Myopathies 1998, University Press, Camridge.
14. Brooks S.P., Storey K.B. Bound and determined: a computer program for making buffers of defined ion concentrations. Anal. Biochem. 1992, 201:119-126.
15. Capote J., Bolanos P., Schuhmeier R.P., Melzer W., Caputo C. Calcium transients in developing mouse skeletal muscle fibres. J. Physiol. 2005, 564:451-464.
16. 2+ transients in amphibian and mammalian muscle fibres. J. Muscle Res. Cell Motil. 2004, 25:315-328.
17. Carpenter S. Inclusion body myositis, a review. J. Neuropathol. Exp. Neurol. 1996, 55:1105-1114.
18. Casley C.S., Canevari L., Land J.M., Clark J.B., Sharpe M.A. Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochem. 2002, 80:91-100.
19. Chan S.L., Mayne M., Holden C.P., Geiger J.D., Mattson M.P. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J. Biol. Chem. 2000, 275:18195-18200.
20. Christensen R.A., Shtifman A., Allen P.D., Lopez J.R., Querfurth H.W. Calcium dyshomeostasis in beta-amyloid and tau-bearing skeletal myotubes. J. Biol. Chem. 2004, 279:53524-53532.
21. Engel W.K., Askanas V. Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology 2006, 66:S20-29.
22. Grant S.M., Shankar S.L., Chalmers-Redman R.M., Tatton W.G., Szyf M., Cuello A.C. Mitochondrial abnormalities in neuroectodermal cells stably expressing human amyloid precursor protein (hAPP751). Neuroreport 1999, 10:41-46.
23. Ikemoto N., Kim D.H., Antoniu B. Measurement of calcium release in isolated membrane systems: coupling between the transverse tubule and sarcoplasmic reticulum. Methods Enzymol. 1988, 157:469-480.
24. Kelliher M., Fastbom J., Cowburn R.F., Bonkale W., Ohm T.G., Ravid R., Sorrentino V., O'Neill C. Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies. Neuroscience 1999, 92:499-513.
25. LaFerla F.M. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci. 2002, 3:862-872.
26. Laver D.R., Lenz G.K., Lamb G.D. Regulation of the calcium release channel from rabbit skeletal muscle by the nucleotides ATP, AMP, IMP and adenosine. J. Physiol. 2001, 537:763-778.
27. 2+ inhibition of skeletal RyRs reconstituted as isolated channels or coupled clusters. J. Gen. Physiol. 2004, 124:741-758.
28. 2+ inhibits the ryanodine receptor from cardiac muscle. J. Membr. Biol. 1995, 147:7-22.
29. 2+] in adult Alzheimer's disease mice. J. Neurochem. 2008, 105:262-271.
30. Marks P.W., Maxfield F.R. Preparation of solutions with free calcium concentration in the nanomolar range using 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid. Anal. Biochem. 1991, 193:61-71.
31. Mattson M.P., LaFerla F.M., Chan S.L., Leissring M.A., Shepel P.N., Geiger J.D. Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2000, 23:222-229.
32. McFerrin J., Engel W.K., Askanas V. Impaired innervation of cultured human muscle overexpressing betaAPP experimentally and genetically: relevance to inclusion-body myopathies. Neuroreport 1998, 9:3201-3205.
33. 2+ ions in excitation-contraction coupling of skeletal muscle fibres. Biochim. Biophys. Acta 1995, 1241:59-116.
34. Mendez J., Keys A. Density and composition of mammalian muscle. Metabolism 1960, 9:184-188.
35. Moussa C.E., Fu Q., Kumar P., Shtifman A., Lopez J.R., Allen P.D., LaFerla F., Weinberg D., Magrane J., Aprahamian T., Walsh K., Rosen K.M., Querfurth H.W. Transgenic expression of beta-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology. FASEB J. 2006, 20:2165-2167.
36. O'Neill E.R., Sakowska M.M., Laver D.R. Regulation of the calcium release channel from skeletal muscle by suramin and the disulfonated stilbene derivatives DIDS, DBDS, and DNDS. Biophys. J. 2003, 84:1674-1689.
37. Pette D., Staron R.S. Transitions of muscle fiber phenotypic profiles. Histochem. Cell Biol. 2001, 115:359-372.
38. Pierrot N., Ghisdal P., Caumont A.S., Octave J.N. Intraneuronal amyloid-beta1-42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death. J. Neurochem. 2004, 88:1140-1150.
39. Sarkozi E., Askanas V., Johnson S.A., Engel W.K., Alvarez R.B. beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport 1993, 4:815-818.
40. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
41. 2+ release in the 3× Tg-AD mouse model of Alzheimer's disease. J. Neurochem. 2005, 94:1711-1718.
42. Spangenburg E.E., Ward C.W., Williams J.H. Effects of lactate on force production by mouse EDL muscle: implications for the development of fatigue. Can. J. Physiol. Pharmacol. 1998, 76:642-648.
43. 2+ disruptions in young, adult, and aged Alzheimer's disease mice. J. Neurosci. 2006, 26:5180-5189.
44. Stutzmann G.E., Smith I., Caccamo A., Oddo S., Parker I., Laferla F. Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer's mouse models. Ann. N.Y. Acad. Sci. 2007, 1097:265-277.
45. Sugarman M.C., Kitazawa M., Baker M., Caiozzo V.J., Querfurth H.W., LaFerla F.M. Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiol. Aging 2006, 27:423-432.
46. Sugarman M.C., Yamasaki T.R., Oddo S., Echegoyen J.C., Murphy M.P., Golde T.E., Jannatipour M., Leissring M.A., LaFerla F.M. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:6334-6339.
47. 2+ channels: a possible involvement of free radicals. J. Neurochem. 1997, 68:265-271.
48. 2+ channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture. J. Neurochem. 1994, 62:372-375.
49. Westerblad H., Allen D.G. Cellular mechanisms of skeletal muscle fatigue. Adv. Exp. Med. Biol. 2003, 538:563-570. discussion 571.